Molecular diagnosis in autoimmune skin blistering conditions

Current Molecular Medicine

Volumn 14, Issue 1, 2014, Pages 69-95

  Otten, J V ^a   Hashimoto, T ^b   Hertl, M ^c   Payne, A S ^d   Sitaru, C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b KURUME UNIVERSITY   (Japan)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Autoantibodies; Autoantigens; Basement membrane; Desmosome; ELISA; Extracellular matrix; Hemidesmosome; Immunoassay; Immunoblotting; Immunofluorescence microscopy

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 2 MACROGLOBULINE LIKE 1; AMIODARONE; ATORVASTATIN; AUTOANTIGEN; DESMOCOLLIN; DESMOGLEIN 3; DESMOPLAKIN; DICLOFENAC; ENVOPLAKIN; IMMUNOGLOBULIN A; LITHIUM CARBONATE; PENICILLAMINE; PENICILLIN G; PERIPLAKIN; PHENYTOIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SULTAMICILLIN; UNCLASSIFIED DRUG; VANCOMYCIN; COTRIMOXAZOLE; DESMOGLEIN 1;

AUTOIMMUNE SKIN DISEASE; BLISTER; BULLOUS PEMPHIGOID; DERMATITIS HERPETIFORMIS; DESMOSOME; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDERMOLYSIS BULLOSA ACQUISITA; EXTRACELLULAR MATRIX; HEMIDESMOSOME; HUMAN; IMMUNOASSAY; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOPATHOLOGY; MUCOUS MEMBRANE PEMPHIGOID; NONHUMAN; PARANEOPLASTIC PEMPHIGUS; PEMPHIGOID; PEMPHIGOID GESTATIONIS; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; REVIEW; ARTICLE; AUTOIMMUNE DISEASE; CHROMATIN IMMUNOPRECIPITATION; HAILEY HAILEY DISEASE; HISTOPATHOLOGY; IMMUNOFLUORESCENCE TEST; LINEAR IGA BULLOUS DERMATOSIS; MICROARRAY ANALYSIS; MICROSCOPY; MOLECULAR DIAGNOSIS; OUTCOME ASSESSMENT;

AUTOIMMUNE DISEASES; BLISTER; HUMANS;

EID: 84891854115     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/15665240113136660079     Document Type: Review

References (244)

1. Mihai S, Sitaru C. Immunopathology and molecular diagnosis of autoimmune bullous diseases. J Cell Mol Med 2007; 11: 462-481.
2. Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: Clinical manifestations. J Dtsch Dermatol Ges 2011; 9: 844-56; quiz 857.
3. Sitaru C, Zillikens D. Mechanisms of blister induction by autoantibodies. Exp Dermatol 2005; 14: 861-875.
4. Waschke J. The desmosome and pemphigus. Histochem Cell Biol 2008; 130: 21-54.
5. Van Agtmael T, Bruckner-Tuderman L. Basement membranes and human disease. Cell Tissue Res 2010; 339: 167-188.
6. Arndt KA, Feingold DS. The sign of Pyotr Vasilyewich Nikolsky. N Engl J Med 1970; 282: 1154-1155.
7. Doubleday CW. Who is Nikolsky and what does his sign mean?. J Am Acad Dermatol 1987; 16: 1054-1055.
8. Kelly B, Shimoni T. Reintroducing the Tzanck smear. Am J Clin Dermatol 2009; 10: 141-152.
9. Durdu M, Baba M, Seçkin D. The value of Tzanck smear test in diagnosis of erosive, vesicular, bullous, and pustular skin lesions. J Am Acad Dermatol 2008; 59: 958-964.
10. Florea F, Sitaru C. Relevance of immunofluorescence methods in clinical dermatology. CML Dermatology 2011; 15: 29-45.
11. Gammon WR, Briggaman RA, Inman AO, Queen LL, Wheeler CE. Differentiating anti-lamina lucida and antisublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin. J Invest Dermatol 1984; 82: 139-144.
12. Gammon WR, Briggaman RA, Inman AO3 et al. Differentiating anti-lamina lucida and anti-sublamina densa anti-bmz antibodies by indirect immunofluorescence on 1.0 m sodium chloride-separated skin. J. Invest. Dermatol. 1984; 82: 139-144.
13. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323: 1729-1735.
14. Domloge-Hultsch N, Gammon WR, Briggaman RA, Gil SG, Carter WG, Yancey KB. Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease. J Clin Invest 1992; 90: 1628-1633.
15. Caldarola G, Kneisel A, Hertl M, Feliciani C. Herpes simplex virus infection in pemphigus vulgaris: clinical and immunological considerations. Eur J Dermatol 2008; 18: 440-443.
16. Stevenson ML, Levitt JO. Acute zoster in known pemphigus vulgaris and bullous pemphigoid: avoiding the disease flare trap. J Am Acad Dermatol 2011; 64: e125-6.
17. Raith L. [Johann Ernst Wichmann--an unjustly little-known dermatologist of the 18th century]. Dermatol Monatsschr 1983; 169: 725-727.
18. Holubar K. Pemphigus: a disease of man and animal. Historical and other perspectives. Int J Dermatol 1988; 27: 516-520.
19. Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med 2006; 355: 1800-1810.
20. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991; 67: 869-877.
21. Ding X, Aoki V, Mascaro JMJ, Lopez-Swiderski A, Diaz LA, Fairley JA. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol 1997; 109: 592-596.
22. Nguyen VT, Ndoye A, Grando SA. Pemphigus vulgaris antibody identifies pemphaxin. A novel keratinocyte annexin-like molecule binding acetylcholine. J Biol Chem 2000; 275: 29466-29476.
23. Nguyen VT, Ndoye A, Grando SA. Novel human alpha9 acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity. Am J Pathol 2000; 157: 1377-1391.
24. Rafei D, Müller R, Ishii N, Llamazares M, Hashimoto T, Hertl M, Eming R. IgG autoantibodies against desmocollin 3 in pemphigus sera induce loss of keratinocyte adhesion. Am J Pathol 2011; 178: 718-723.
25. Mao X, Nagler AR, Farber SA, Choi EJ, Jackson LH, Leiferman KM, Ishii N, Hashimoto T, Amagai M, Zone JJ, Payne AS. Autoimmunity to desmocollin 3 in pemphigus vulgaris. Am J Pathol 2010; 177: 2724-2730.
26. Ishii K, Amagai M, Hall RP, et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997; 159: 2010-2017.
27. Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999; 40: 167-170.
28. Nagel A, Lang A, Engel D, et al. Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. Clin Immunol 2010; 134: 320-330.
29. Dhandha MM, Seiffert-Sinha K, Sinha AA. Specific immunoglobulin isotypes correlate with disease activity, morphology, duration and hla association in pemphigus vulgaris. Autoimmunity 2012; 45: 516-526.
30. Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J. Clin. Invest. 2006; 116: 1159-1166.
31. Sinha AA. Constructing immunoprofiles to deconstruct disease complexity in pemphigus. Autoimmunity 2012; 45: 36-43.
32. Veldman C, Höhne A, Dieckmann D et al. Type i regulatory t cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with pemphigus vulgaris. J. Immunol. 2004; 172: 6468-6475.
33. Brenner S, Bialy-Golan A, Ruocco V. Drug-induced pemphigus. Clin. Dermatol. 1998; 16: 393-397.
34. Brenner S, Goldberg I. Drug-induced pemphigus. Clin. Dermatol. 2011; 29: 455-457.
35. Feng S, Zhou W, Zhang J et al. Analysis of 6 cases of drug-induced pemphigus. Eur J Dermatol 2011; 21: 696-699.
36. Fryer EJ, Lebwohl M. Pemphigus vulgaris after initiation of psoralen and uva therapy for psoriasis. J. Am. Acad. Dermatol. 1994; 30: 651-653.
37. Jamora MJJ, Jiao D, Bystryn J. Antibodies to desmoglein 1 and 3, and the clinical phenotype of pemphigus vulgaris. J Am Acad Dermatol 2003; 48: 976-977.
38. Lebeau S, Müller R, Masouyé I, Hertl M, Borradori L. Pemphigus herpetiformis: analysis of the autoantibody profile during the disease course with changes in the clinical phenotype. Clin Exp Dermatol 2010; 35: 366-372.
39. Eyre RW, Stanley JR. Identification of pemphigus vulgaris antigen extracted from normal human epidermis and comparison with pemphigus foliaceus antigen. J Clin Invest 1988; 81: 807-812.
40. Rock B, Martins CR, Theofilopoulos AN, et al. The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem). N Engl J Med 1989; 320: 1463-1469.
41. Aoki V, Sousa JXJ, Diaz LA. Pathogenesis of endemic pemphigus foliaceus. Dermatol Clin 2011; 29: 413-8, viii.
42. Aoki V, Millikan RC, Rivitti EA, Hans-Filho G, Eaton DP, Warren SJP, Li N, Hilario-Vargas J, Hoffmann RG, Diaz LA. Environmental risk factors in endemic pemphigus foliaceus (fogo selvagem). J Investig Dermatol Symp Proc 2004; 9: 34-40.
43. Qian Y, Jeong JS, Maldonado M et al. Cutting edge: brazilian pemphigus foliaceus anti-desmoglein 1 autoantibodies cross-react with sand fly salivary ljm11 antigen. J. Immunol. 2012; 189: 1535-1539.
44. Nguyen VT, Ndoye A, Bassler KD, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol 2001; 137: 193-206.
45. Maldonado F, Pittelkow MR, Ryu JH. Constrictive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome. Respirology 2009; 14: 129-133.
46. Anhalt GJ. Paraneoplastic pemphigus: the role of tumours and drugs. Br J Dermatol 2001; 144: 1102-1104.
47. Maverakis E, Goodarzi H, Wehrli LN, Ono Y, Garcia MS. The Etiology of Paraneoplastic Autoimmunity. Clin Rev Allergy Immunol 2011; 42: 135-144.
48. Vanderlugt CJ, Miller SD. Epitope spreading. Curr Opin Immunol 1996; 8: 831-836.
49. Chan LS, Vanderlugt CJ, Hashimoto T, et al. Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol 1998; 110: 103-109.
50. Zhang J, Qiao Q, Chen X, et al. Improved outcomes after complete resection of underlying tumors for patients with paraneoplastic pemphigus: a single-center experience of 22 cases. J Cancer Res Clin Oncol 2011; 137: 229-234.
51. Meyers SJ, Varley GA, Meisler DM, Camisa C, Wander AH. Conjunctival involvement in paraneoplastic pemphigus. Am J Ophthalmol 1992; 114: 621-624.
52. Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc 2004; 9: 29-33.
53. Frew JW, Murrell DF. Paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome): clinical presentations and pathogenesis. Dermatol Clin 2011; 29: 419-25, viii.
54. Zhu X, Zhang B. Paraneoplastic pemphigus. J Dermatol 2007; 34: 503-511.
55. Nousari HC, Deterding R, Wojtczack H, et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med 1999; 340: 1406-1410.
56. Helou J, Allbritton J, Anhalt GJ. Accuracy of indirect immunofluorescence testing in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol 1995; 32: 441-447.
57. Kim SC, Kwon YD, Lee IJ, Chang SN, Lee TG. cDNA cloning of the 210-kDa paraneoplastic pemphigus antigen reveals that envoplakin is a component of the antigen complex. J Invest Dermatol 1997; 109: 365-369.
58. Kiyokawa C, Ruhrberg C, Nie Z, et al. Envoplakin and periplakin are components of the paraneoplastic pemphigus antigen complex. J Invest Dermatol 1998; 111: 1236-1238.
59. Mahoney MG, Aho S, Uitto J, Stanley JR. The members of the plakin family of proteins recognized by paraneoplastic pemphigus antibodies include periplakin. J Invest Dermatol 1998; 111: 308-313.
60. Schepens I, Jaunin F, Begre N, et al. The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human. PLoS ONE 2010; 5: e12250.
61. Hashimoto T, Amagai M, Watanabe K, et al. Characterization of paraneoplastic pemphigus autoantigens by immunoblot analysis. J Invest Dermatol 1995; 104: 829-834.
62. Sitaru C, Dähnrich C, Probst C, et al. Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp Dermatol 2007; 16: 770-777.
63. Tsuruta D, Ishii N, Hamada T, et al. IgA pemphigus. Clin Dermatol 2011; 29: 437-442.
64. Hashimoto T, Ebihara T, Nishikawa T. Studies of autoantigens recognized by IgA anti-keratinocyte cell surface antibodies. J Dermatol Sci 1996; 12: 10-17.
65. Hashimoto T, Kiyokawa C, Mori O, et al. Human desmocollin 1 (Dsc1) is an autoantigen for the subcorneal pustular dermatosis type of IgA pemphigus. J Invest Dermatol 1997; 109: 127-131.
66. Kárpáti S, Amagai M, Liu WL, Dmochowski M, Hashimoto T, Horváth A. Identification of desmoglein 1 as autoantigen in a patient with intraepidermal neutrophilic IgA dermatosis type of IgA pemphigus. Exp Dermatol 2000; 9: 224-228.
67. Hashimoto T, Komai A, Futei Y, Nishikawa T, Amagai M. Detection of IgA autoantibodies to desmogleins by an enzyme-linked immunosorbent assay: the presence of new minor subtypes of IgA pemphigus. Arch Dermatol 2001; 137: 735-738.
68. Wang J, Kwon J, Ding X, Fairley JA, Woodley DT, Chan LS. Nonsecretory IgA1 autoantibodies targeting desmosomal component desmoglein 3 in intraepidermal neutrophilic IgA dermatosis. Am J Pathol 1997; 150: 1901-1907.
69. Ishii N, Ishida-Yamamoto A, Hashimoto T. Immunolocalization of target autoantigens in IgA pemphigus. Clin Exp Dermatol 2004; 29: 62-66.
70. Supapannachart N, Mutasim DF. The distribution of IgA pemphigus antigen in human skin and the role of IgA anti-cell surface antibodies in the induction of intraepidermal acantholysis. Arch Dermatol 1993; 129: 605-608.
71. Hashimoto T, Yasumoto S, Nagata Y, Okamoto T, Fujita S. Clinical, histopathological and immunological distinction in two cases of IgA pemphigus. Clin Exp Dermatol 2002; 27: 636-640.
72. Bernard P, Vaillant L, Labeille B, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 1995; 131: 48-52.
73. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJP, West J. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study. BMJ 2008; 337: a180.
74. Baican A, Baican C, Chiriac G, et al. Pemphigus vulgaris is the most common autoimmune bullous disease in Northwestern Romania. Int J Dermatol 2010; 49: 768-774.
75. Olasz EB, Yancey KB. Bullous pemphigoid and related subepidermal autoimmune blistering diseases. Curr Dir Autoimmun 2008; 10: 141-166.
76. Lever W. Pemphigus. Medicine 1953; 32: 2-132.
77. Stanley JR, Hawley-Nelson P, Yuspa SH, Shevach EM, Katz SI. Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell 1981; 24: 897-903.
78. Diaz LA, Ratrie H, Saunders WS, et al. Isolation of a human epidermal cDNA corresponding to the 180-kDa autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. J Clin Invest 1990; 86: 1088-1094.
79. Laffitte E, Favre B, Fontao L, et al. Plectin, an unusual target antigen in bullous pemphigoid. Br J Dermatol 2001; 144: 136-138.
80. Kiss M, Perényi A, Marczinovits I, et al. Autoantibodies to human alpha6 integrin in patients with bullous pemphigoid. Ann N Y Acad Sci 2005; 1051: 104-110.
81. Giudice GJ, Emery DJ, Zelickson BD, Anhalt GJ, Liu Z, Diaz LA. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the {BP}180 ectodomain. J Immunol 1993; 151: 5742-5750.
82. Murakami H, Amagai M, Higashiyama M, et al. Analysis of antigens recognized by autoantibodies in herpes gestationis. Usefulness of immunoblotting using a fusion protein representing an extracellular domain of the 180 kD bullous pemphigoid antigen. J Dermatol Sci 1996; 13: 112-117.
83. Sitaru C. Bullous pemphigoid: a prototypical antibody-mediated organ-specific autoimmune disease. J Invest Dermatol 2009; 129: 822-824.
84. Feliciani C, Caldarola G, Kneisel A, et al. IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses. Br J Dermatol 2009; 161: 306-312.
85. Quartey-Papafio CM, Hudson PM. Bullous pemphigoid initially localized to sites of burns (scalds) in a patient on sulphasalazine for ulcerative colitis. Clin Exp Dermatol 1994; 19: 281.
86. Vande Maele DM, Reilly JC. Bullous pemphigoid at colostomy site: report of a case. Dis Colon Rectum 1997; 40: 370-371.
87. Torchia D, Caproni M, Ketabchi S, Antiga E, Fabbri P. Bullous pemphigoid initially localized around a urostomy. Int J Dermatol 2006; 45: 1387-1389.
88. Batalla A, Peón G, De la Torre C. Localized bullous pemphigoid at urostomy site. Indian J Dermatol Venereol Leprol 2011; 77: 625.
89. Pardo J, Rodrguez-Serna M, Mercader P, Fortea JM. Localized bullous pemphigoid overlying a fistula for hemodialysis. J Am Acad Dermatol 2004; 51: S131-2.
90. Brodell RT, Korman NJ. Stump pemphigoid. Cutis 1996; 57: 245-246.
91. Melani L, Giomi B, Antiga E, Torchia D, Caproni M, Fabbri P. Radiation therapy as a trigger factor for initially localized bullous pemphigoid. Breast J 2005; 11: 485-486.
92. Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 2002; 30: 224-232.
93. Yoshida M, Hamada T, Amagai M, et al. Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. J Dermatol Sci 2006; 41: 21-30.
94. Iwata Y, Komura K, Kodera M, et al. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol 2008; 144: 41-48.
95. Messingham KAN, Noe MH, Chapman MA, Giudice GJ, Fairley JA. A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid. J Immunol Methods 2009; 346: 18-25.
96. Dresow SK, Sitaru C, Recke A, Oostingh GJ, Zillikens D, Gibbs BF. IgE autoantibodies against the intracellular domain of BP180. Br J Dermatol 2009; 160: 429-432.
97. Intong LRA, Murrell DF. Pemphigoid gestationis: pathogenesis and clinical features. Dermatol Clin 2011; 29: 447-52, ix.
98. Morrison LH, Labib RS, Zone JJ, Diaz LA, Anhalt GJ. Herpes gestationis autoantibodies recognize a 180-kD human epidermal antigen. J Clin Invest 1988; 81: 2023-2026.
99. Kelly SE, Bhogal BS, Wojnarowska F, Whitehead P, Leigh IM, Black MM. Western blot analysis of the antigen in pemphigoid gestationis. Br J Dermatol 1990; 122: 445-449.
100. Katz SI, Hertz KC, Yaoita H. Herpes gestationis. Immunopathology and characterization of the HG factor. J Clin Invest 1976; 57: 1434-1441.
101. Jordon RE, Heine KG, Tappeiner G, Bushkell LL, Provost TT. The immunopathology of herpes gestationis. Immunofluorescence studies and characterization of HG factor. J Clin Invest 1976; 57: 1426-1431.
102. Kelly SE, Cerio R, Bhogal BS, Black MM. The distribution of IgG subclasses in pemphigoid gestationis: PG factor is an IgG1 autoantibody. J Invest Dermatol 1989; 92: 695-698.
103. Sitaru C, Powell J, Shimanovich I, et al. Pemphigoid gestationis: maternal sera recognize epitopes restricted to the N-terminal portion of the extracellular domain of BP180 not present on its shed ectodomain. Br J Dermatol 2003; 149: 420-422.
104. Carruthers JA. Herpes gestationis: clinical features of immunologically proved cases. Am J Obstet Gynecol 1978; 131: 865-867.
105. Amato L, Mei S, Gallerani I, Moretti S, Fabbri P. A case of chronic herpes gestationis: persistent disease or conversion to bullous pemphigoid?. J Am Acad Dermatol 2003; 49: 302-307.
106. Boulinguez S, Bédane C, Prost C, Bernard P, Labbé L, Bonnetblanc JM. Chronic pemphigoid gestationis: comparative clinical and immunopathological study of 10 patients. Dermatology 2003; 206: 113-119.
107. Semkova K, Black M. Pemphigoid gestationis: current insights into pathogenesis and treatment. Eur J Obstet Gynecol Reprod Biol 2009; 145: 138-144.
108. Jenkins RE, Hern S, Black MM. Clinical features and management of 87 patients with pemphigoid gestationis. Clin Exp Dermatol 1999; 24: 255-259.
109. Ambros-Rudolph CM, Müllegger RR, Vaughan-Jones SA, Kerl H, Black MM. The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients. J Am Acad Dermatol 2006; 54: 395-404.
110. Roth M. Pregnancy dermatoses: diagnosis, management, and controversies. Am J Clin Dermatol 2011; 12: 25-41.
111. Beard MP, Millington GWM. Recent developments in the specific dermatoses of pregnancy. Clin Exp Dermatol 2011; 37: 1-4.
112. Sitaru C, Powell J, Messer G, Bröcker E, Wojnarowska F, Zillikens D. Immunoblotting and enzyme-linked immunosorbent assay for the diagnosis of pemphigoid gestationis. Obstet Gynecol 2004; 103: 757-763.
113. Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138: 370-379.
114. Egan CA, Lazarova Z, Darling TN, Yee C, Coté T, Yancey KB. Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet 2001; 357: 1850-1851.
115. Bernard P, Prost C, Durepaire N, Basset-Seguin N, Didierjean L, Saurat JH. The major cicatricial pemphigoid antigen is a 180-kD protein that shows immunologic cross-reactivities with the bullous pemphigoid antigen. J Invest Dermatol 1992; 99: 174-179.
116. Balding SD, Prost C, Diaz LA, et al. Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. J Invest Dermatol 1996; 106: 141-146.
117. Murakami H, Nishioka S, Setterfield J, et al. Analysis of antigens targeted by circulating IgG and IgA autoantibodies in 50 patients with cicatricial pemphigoid. J Dermatol Sci 1998; 17: 39-44.
118. Tyagi S, Bhol K, Natarajan K, Livir-Rallatos C, Foster CS, Ahmed AR. Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization. Proc Natl Acad Sci U S A 1996; 93: 14714-14719.
119. Caux F, Kirtschig G, Lemarchand-Venencie F, et al. IgA-epidermolysis bullosa acquisita in a child resulting in blindness. Br J Dermatol 1997; 137: 270-275.
120. Wieme N, Lambert J, Moerman M, Geerts ML, Temmerman L, Naeyaert JM. Epidermolysis bullosa acquisita with combined features of bullous pemphigoid and cicatricial pemphigoid. Dermatology 1999; 198: 310-313.
121. Schmidt E, Skrobek C, Kromminga A, et al. Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180. Br J Dermatol 2001; 145: 778-783.
122. Leverkus M, Bhol K, Hirako Y, et al. Cicatricial pemphigoid with circulating autoantibodies to beta4 integrin, bullous pemphigoid 180 and bullous pemphigoid 230. Br J Dermatol 2001; 145: 998-1004.
123. Rashid KA, Gürcan HM, Ahmed AR. Antigen specificity in subsets of mucous membrane pemphigoid. J Invest Dermatol 2006; 126: 2631-2636.
124. Egan CA, Lazarova Z, Darling TN, Yee C, Yancey KB. Anti-epiligrin cicatricial pemphigoid: clinical findings, immunopathogenesis, and significant associations. Medicine (Baltimore) 2003; 82: 177-186.
125. Hanno R, Foster DR, Bean SF. Brunsting-Perry cicatricial pemphigoid associated with bullous pemphigoid. J Am Acad Dermatol 1980; 3: 470-473.
126. Rose C, Schmidt E, Kerstan A, et al. Histopathology of anti-laminin 5 mucous membrane pemphigoid. J Am Acad Dermatol 2009; 61: 433-440.
127. Lazarova Z, Sitaru C, Zillikens D, Yancey KB. Comparative analysis of methods for detection of anti-laminin 5 autoantibodies in patients with anti-epiligrin cicatricial pemphigoid. J Am Acad Dermatol 2004; 51: 886-892.
128. Lazarova Z, Yee C, Lazar J, Yancey KB. IgG autoantibodies in patients with anti-epiligrin cicatricial pemphigoid recognize the G domain of the laminin 5 alpha-subunit. Clin Immunol 2001; 101: 100-105.
129. Bhol KC, Dans MJ, Simmons RK, Foster CS, Giancotti FG, Ahmed AR. The autoantibodies to alpha 6 beta 4 integrin of patients affected by ocular cicatricial pemphigoid recognize predominantly epitopes within the large cytoplasmic domain of human beta 4. J Immunol 2000; 165: 2824-2829.
130. Bhol KC, Goss L, Kumari S, Colon JE, Ahmed AR. Autoantibodies to human alpha6 integrin in patients with oral pemphigoid. J Dent Res 2001; 80: 1711-1715.
131. Chorzelski TP, Jablonska S. IgA linear dermatosis of childhood (chronic bullous disease of childhood). Br J Dermatol 1979; 101: 535-542.
132. Fortuna G, Salas-Alanis JC, Guidetti E, Marinkovich MP. A critical reappraisal of the current data on drug-induced linear immuglobulin A bullous dermatosis: A real and separate nosological entity? J Am Acad Dermatol 2012; 66(6): 988-94.
133. Zone JJ, Taylor TB, Kadunce DP, Meyer LJ. Identification of the cutaneous basement membrane zone antigen and isolation of antibody in linear immunoglobulin A bullous dermatosis. J Clin Invest 1990; 85: 812-820.
134. Marinkovich MP, Taylor TB, Keene DR, Burgeson RE, Zone JJ. LAD-1, the linear IgA bullous dermatosis autoantigen, is a novel 120-kDa anchoring filament protein synthesized by epidermal cells. J Invest Dermatol 1996; 106: 734-738.
135. Pas HH, Kloosterhuis GJ, Heeres K, van der Meer JB, Jonkman MF. Bullous pemphigoid and linear IgA dermatosis sera recognize a similar 120-kDa keratinocyte collagenous glycoprotein with antigenic cross-reactivity to BP180. J Invest Dermatol 1997; 108: 423-429.
136. Hirako Y, Usukura J, Uematsu J, Hashimoto T, Kitajima Y, Owaribe K. Cleavage of BP180, a 180-kDa bullous pemphigoid antigen, yields a 120-kDa collagenous extracellular polypeptide. J Biol Chem 1998; 273: 9711-9717.
137. Schäcke H, Schumann H, Hammami-Hauasli N, Raghunath M, Bruckner-Tuderman L. Two forms of collagen XVII in keratinocytes. A full-length transmembrane protein and a soluble ectodomain. J Biol Chem 1998; 273: 25937-25943.
138. Csorba K, Schmidt S, Florea F, et al. Development of an ELISA for sensitive and specific detection of IgA autoantibodies against BP180 in pemphigoid diseases. Orphanet J Rare Dis 2011; 6: 31.
139. Vodegel RM, de Jong MCJM, Pas HH, Jonkman MF. IgA-mediated epidermolysis bullosa acquisita: two cases and review of the literature. J Am Acad Dermatol 2002; 47: 919-925.
140. van der Steen LP, Bakema JE, Sesarman A et al. Blocking fcα receptor i on granulocytes prevents tissue damage induced by iga autoantibodies. J. Immunol. 2012; 189: 1594-1601.
141. Schumann H, Baetge J, Tasanen K, et al. The shed ectodomain of collagen XVII/BP180 is targeted by autoantibodies in different blistering skin diseases. Am J Pathol 2000; 156: 685-695.
142. Florea F, Torio-Padron N, Hashimoto T, Sitaru C. Non-scarring skin blistering disease and mucosal lesions with IgA autoantibodies reactive with collagen VII and IgG reactivity with laminin γ2. Br J Dermatol 2012; 167(4): 938-41.
143. Zillikens D, Kawahara Y, Ishiko A, et al. A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. J Invest Dermatol 1996; 106: 1333-1338.
144. Dainichi T, Kurono S, Ohyama B, et al. Anti-laminin gamma-1 pemphigoid. Proc Natl Acad Sci U S A 2009; 106: 2800-2805.
145. Dainichi T, Koga H, Tsuji T, et al. From anti-p200 pemphigoid to anti-laminin gamma1 pemphigoid. J Dermatol 2010; 37: 231-238.
146. Zillikens D, Ishiko A, Jonkman MF, et al. Autoantibodies in anti-p200 pemphigoid stain skin lacking laminin 5 and type VII collagen. Br J Dermatol 2000; 143: 1043-1049.
147. Liu Y, Shimizu H, Hashimoto T. Immunofluorescence studies using skin sections of recessive dystrophic epidermolysis bullosa patients indicated that the antigen of anti-p200 pemphigoid is not a fragment of type VII collagen. J Dermatol Sci 2003; 32: 125-129.
148. Koga H, Ishii N, Dainichi T, et al. An attempt to develop mouse model for anti-laminin γ1 pemphigoid. J Dermatol Sci 2013; 70: 108-15.
149. Dilling A, Rose C, Hashimoto T, Zillikens D, Shimanovich I. Anti-p200 pemphigoid: a novel autoimmune subepidermal blistering disease. J Dermatol 2007; 34: 1-8.
150. Groth S, Recke A, Vafia K, et al. Development of a simple enzyme-linked immunosorbent assay for the detection of autoantibodies in anti-p200 pemphigoid. Br J Dermatol 2011; 164: 76-82.
151. Woodley DT, Briggaman RA, O'Keefe EJ, Inman AO, Queen LL, Gammon WR. Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med 1984; 310: 1007-1013.
152. Ishii N, Hamada T, Dainichi T, et al. Epidermolysis bullosa acquisita: what's new?. J Dermatol 2010; 37: 220-230.
153. Sitaru C. Experimental models of epidermolysis bullosa acquisita. Exp Dermatol 2007; 16: 520-531.
154. Remington J, Chen M, Burnett J, Woodley DT. Autoimmunity to type VII collagen: epidermolysis bullosa acquisita. Curr Dir Autoimmun 2008; 10: 195-205.
155. Caux F. Diagnosis and clinical features of epidermolysis bullosa acquisita. Dermatol Clin 2011; 29: 485-91, x.
156. Luke MC, Darling TN, Hsu R, et al. Mucosal morbidity in patients with epidermolysis bullosa acquisita. Arch Dermatol 1999; 135: 954-959.
157. Hundorfean G, Neurath MF, Sitaru C. Autoimmunity against type VII collagen in inflammatory bowel disease. J Cell Mol Med 2010; 14: 2393-2403.
158. Chen M, Chan LS, Cai X, O'Toole EA, Sample JC, Woodley DT. Development of an ELISA for rapid detection of anti-type VII collagen autoantibodies in epidermolysis bullosa acquisita. J Invest Dermatol 1997; 108: 68-72.
159. Saleh MA, Ishii K, Kim Y, et al. Development of NC1 and NC2 domains of type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients. J Dermatol Sci 2011; 62: 169-175.
160. Pendaries V, Gasc G, Titeux M, et al. Immune reactivity to type VII collagen: implications for gene therapy of recessive dystrophic epidermolysis bullosa. Gene Ther 2010; 17: 930-937.
161. Licarete E, Ganz S, Recknagel M, et al. Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseases. BMC Immunol 2012; 13: 16.
162. Reunala TL. Dermatitis herpetiformis. Clin Dermatol 2001; 19: 728-736.
163. Kárpáti S. An exception within the group of autoimmune blistering diseases: dermatitis herpetiformis, the glutensensitive dermopathy. Dermatol Clin 2011; 29: 463-8, x.
164. Reunala T. Dermatitis herpetiformis: coeliac disease of the skin. Ann Med 1998; 30: 416-418.
165. Caproni M, Antiga E, Melani L, Fabbri P. Guidelines for the diagnosis and treatment of dermatitis herpetiformis. J Eur Acad Dermatol Venereol 2009; 23: 633-638.
166. Dieterich W, Laag E, Bruckner-Tuderman L, et al. Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis. J Invest Dermatol 1999; 113: 133-136.
167. Sárdy M, Kárpáti S, Merkl B, Paulsson M, Smyth N. Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 2002; 195: 747-757.
168. Zettinig G, Weissel M, Flores J, et al. Dermatitis herpetiformis is associated with atrophic but not with goitrous variant of hashimoto's thyroiditis. Eur. J. Clin. Invest. 2000; 30: 53-57.
169. Nakajima K. Recent advances in dermatitis herpetiformis. Clin. Dev. Immunol. 2012; 2012: 914162.
170. Iwamoto S, Iwamoto AT, Cha J, et al. The utility of the DNA microarray scanner to simplify the immunofluorescence evaluation of autoimmune bullous diseases. Am J Dermatopathol 2009; 31: 218-222.
171. Hiemann R, Büttner T, Krieger T, Roggenbuck D, Sack U, Conrad K. Challenges of automated screening and differentiation of non-organ specific autoantibodies on HEp-2 cells. Autoimmun Rev 2009; 9: 17-22.
172. Sack U, Knoechner S, Warschkau H, Pigla U, Emmrich F, Kamprad M. Computer-assisted classification of HEp-2 immunofluorescence patterns in autoimmune diagnostics. Autoimmun Rev 2003; 2: 298-304.
173. Rigon A, Soda P, Zennaro D, Iannello G, Afeltra A. Indirect immunofluorescence in autoimmune diseases: assessment of digital images for diagnostic purpose. Cytometry B Clin Cytom 2007; 72: 472-477.
174. Soda P, Iannello G. Aggregation of classifiers for staining pattern recognition in antinuclear autoantibodies analysis. IEEE Trans Inf Technol Biomed 2009; 13: 322-329.
175. Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M. Tissue microarray: a new technology for amplification of tissue resources. Cancer J 2001; 7: 24-31.
176. Hart T, Zhao A, Garg A, Bolusani S, Marcotte EM. Human cell chips: adapting DNA microarray spotting technology to cell-based imaging assays. PLoS ONE 2009; 4: e7088.
177. Rosenbach M, Murrell DF, Bystryn J, et al. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol 2009; 129: 2404-2410.
178. Schmidt E, Dähnrich C, Rosemann A, et al. Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Exp Dermatol 2010; 19: 458-463.
179. Huang Y, Bu D, Zhu Y. Sensitive enzyme-linked immunosorbent assay for detection of circulating anti-peri and envo autoantibodies in patients with paraneoplastic pemphigus. J Invest Dermatol 2008; 128: S63.
180. Probst C, Schlumberger W, Stöcker W, et al. Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. Clin Chim Acta 2009; 410: 13-18.
181. Mouquet H, Drenovska K, Lartigue A, et al. Detection and characterization of anti-envoplakin linker autoantibodies in paraneoplastic pemphigus using specific bead-based assay. Clin Immunol 2008; 129: 304-312.
182. Giudice GJ, Wilske KC, Anhalt GJ, et al. Development of an ELISA to detect anti-BP180 autoantibodies in bullous pemphigoid and herpes gestationis. J Invest Dermatol 1994; 102: 878-881.
183. Zillikens D, Mascaro JM, Rose PA, et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 1997; 109: 679-683.
184. Ishiura N, Fujimoto M, Watanabe R, et al. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci 2008; 49: 153-161.
185. Chen M, Chan LS, Cai X, O'Toole EA, Sample JC, Woodley DT. Development of an ELISA for rapid detection of anti-type VII collagen autoantibodies in epidermolysis bullosa acquisita. J Invest Dermatol 1997; 108: 68-72.
186. Komorowski L, Müller R, Vorobyev A, et al. Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita. J Am Acad Dermatol 2013; 68: e89-95.
187. Adornetto G, Volpe G, De Stefano A, et al. An ELIME assay for the rapid diagnosis of coeliac disease. Anal Bioanal Chem 2012; 403: 1191-4.
188. Kasperkiewicz M, Dähnrich C, Probst C, et al. Novel assay for detecting celiac disease-associated autoantibodies in dermatitis herpetiformis using deamidated gliadin-analogous fusion peptides. J Am Acad Dermatol 2012; 66: 583-588.
189. Acostamadiedo JM, Perniciaro C, Rogers RS3. Phenytoin-induced linear IgA bullous disease. J Am Acad Dermatol 1998; 38: 352-356.
190. Armstrong AW, Fazeli A, Yeh SW, Mackool BT, Liu V. Vancomycin-induced linear IgA disease manifesting as bullous erythema multiforme. J Cutan Pathol 2004; 31: 393-397.
191. Bitman LM, Grossman ME, Ross H. Bullous drug eruption treated with amputation. A challenging case of vancomycin-induced linear IgA disease. Arch Dermatol 1996; 132: 1289-1290.
192. Brinkmeier T, Angelkort B, Frosch PJ, Herbst RA. [Vancomycin-induced linear IgA dermatosis]. J Dtsch Dermatol Ges 2003; 1: 212-214.
193. Khan I, Hughes R, Curran S, Marren P. Drug-associated linear IgA disease mimicking toxic epidermal necrolysis. Clin Exp Dermatol 2009; 34: 715-717.
194. Montagnac R, Reguiaï Z, Méhaut S, Bressieux JM, Schillinger F. [Drug induced linear IgA bullous dermatosis]. Nephrologie 2003; 24: 287-292.
195. Palmer RA, Ogg G, Allen J, et al. Vancomycin-induced linear IgA disease with autoantibodies to BP180 and LAD285. Br J Dermatol 2001; 145: 816-820.
196. Whitworth JM, Thomas I, Peltz SA, Sullivan BC, Wolf AH, Cytryn AS. Vancomycin-induced linear IgA bullous dermatosis (LABD). J Am Acad Dermatol 1996; 34: 890-891.
197. Baden LA, Apovian C, Imber MJ, Dover JS. Vancomycin-induced linear IgA bullous dermatosis. Arch Dermatol 1988; 124: 1186-1188.
198. Carpenter S, Berg D, Sidhu-Malik N, Hall RP 3rd, Rico MJ. Vancomycin-associated linear IgA dermatosis. A report of three cases. J Am Acad Dermatol 1992; 26: 45-48.
199. Piketty C, Meeus F, Nochy D, Poux JM, Jacquot C, Bariety J. Linear IgA dermatosis related to vancomycin. Br J Dermatol 1994; 130: 130-131.
200. Geissmann C, Beylot-Barry M, Doutre MS, Beylot C. Drug-induced linear IgA bullous dermatosis. J Am Acad Dermatol 1995; 32: 296.
201. Richards SS, Hall S, Yokel B, Whitmore SE. A bullous eruption in an elderly woman. Vancomycin-associated linear IgA dermatosis (LAD). Arch Dermatol 1995; 131: 1447-8, 1450-1.
202. Espagne E, Prost C, Chosidow O, Saïag P, Revuz J, Roujeau JC. [Linear IgA drug-induced dermatosis. Report of 3 cases]. Ann Dermatol Venereol 1990; 117: 898-899.
203. Jawitz RS, Krach K, Schapiro B. A vesiculobullous eruption in a hospitalized patient. Diagnosis: Drug-induced linear IgA bullous dermatosis (LAD) with eosinophils. Arch Dermatol 2011; 147: 1443, 1448.
204. Kuechle MK, Stegemeir E, Maynard B, Gibson LE, Leiferman KM, Peters MS. Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature. J Am Acad Dermatol 1994; 30: 187-192.
205. Combemale P, Gavaud C, Cozzani E, Nicolas JF, Guennoc B, Dusseau JY. [Linear IgA dermatosis induced by penicillin G]. Ann Dermatol Venereol 1993; 120: 847-848.
206. Wozniak K, Kowalewski C, Hashimoto T, Ishii N, Glinska-Wielochowska M, Schwartz RA. Penicillin-induced anti-p200 pemphigoid: an unusual morphology. Acta Derm Venereol 2006; 86: 443-446.
207. Shimanovich I, Rose C, Sitaru C, Bröcker E, Zillikens D. Localized linear IgA disease induced by ampicillin/sulbactam. J Am Acad Dermatol 2004; 51: 95-98.
208. McWhirter JD, Hashimoto K, Fayne S, Ito K. Linear IgA bullous dermatosis related to lithium carbonate. Arch Dermatol 1987; 123: 1120-1122.
209. Primka EJ 3rd, Liranzo MO, Bergfeld WF, Dijkstra JW. Amiodarone-induced linear IgA disease. J Am Acad Dermatol 1994; 31: 809-811.
210. König C, Eickert A, Scharfetter-Kochanek K, Krieg T, Hunzelmann N. Linear IgA bullous dermatosis induced by atorvastatin. J Am Acad Dermatol 2001; 44: 689-692.
211. Durdu M, Baba M, Seçkin D. A case of bullous pemphigoid induced by aspirin. J Am Acad Dermatol 2011; 65: 443-444.
212. Gabrielsen TO, Staerfelt F, Thune PO. Drug-induced bullous dermatosis with linear IgA deposits along the basement membrane. Acta Derm Venereol 1981; 61: 439-441.
213. Valsecchi R, Serra M, Tornaghi A, Cainelli T. [Drug-induced bullous dermatosis with linear IgA]. G Ital Dermatol Venereol 1982; 117: 221-223.
214. Bialy-Golan A, Brenner S. Penicillamine-induced bullous dermatoses. J Am Acad Dermatol 1996; 35: 732-742.
215. Brenner S, Wolf R, Ruocco V. Drug-induced pemphigus. I. A survey. Clin Dermatol 1993; 11: 501-505.
216. Aghassi D, Dover JS. Pemphigus foliaceus induced by psoralen-UV-A. Arch Dermatol 1998; 134: 1300-1301.
217. Fryer EJ, Lebwohl M. Pemphigus vulgaris after initiation of psoralen and UVA therapy for psoriasis. J Am Acad Dermatol 1994; 30: 651-653.
218. Perl S, Rappersberger K, Födinger D, Anegg B, Hönigsmann H, Ortel B. Bullous pemphigoid induced by PUVA therapy. Dermatology 1996; 193: 245-247.
219. Abel EA, Bennett A. Bullous pemphigoid. Occurrence in psoriasis treated with psoralens plus long-wave ultraviolet radiation. Arch Dermatol 1979; 115: 988-989.
220. Robinson JK, Baughman RD, Provost TT. Bullous pemphigoid induced by PUVA therapy. Is this the aetiology of the acral bullae produced during PUVA treatment?. Br J Dermatol 1978; 99: 709-713.
221. Deschamps P, Pedailles S, Michel M, Leroy D. Photo-induction of lesions in a patient with pemphigus erythematosus. Photodermatol 1984; 1: 38-41.
222. Sanchez-Palacios C, Chan LS. Development of pemphigus herpetiformis in a patient with psoriasis receiving UV-light treatment. J Cutan Pathol 2004; 31: 346-349.
223. Jappe U, Zillikens D, Bonnekoh B, Gollnick H. Epidermolysis bullosa acquisita with ultraviolet radiationsensitivity. Br J Dermatol 2000; 142: 517-520.
224. Kaplan I, Hodak E, Ackerman L, Mimouni D, Anhalt GJ, Calderon S. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol 2004; 40: 553-562.
225. Wang J, Zhu X, Li R, et al. Paraneoplastic pemphigus associated with Castleman tumor: a commonly reported subtype of paraneoplastic pemphigus in China. Arch Dermatol 2005; 141: 1285-1293.
226. Dega H, Laporte JL, Joly P, et al. Paraneoplastic pemphigus associated with Hodgkin's disease. Br J Dermatol 1998; 138: 196-198.
227. Tilakaratne W, Dissanayake M. Paraneoplastic pemphigus: a case report and review of literature. Oral Dis 2005; 11: 326-329.
228. Wang J, Bu DF, Li T, et al. Autoantibody production from a thymoma and a follicular dendritic cell sarcoma associated with paraneoplastic pemphigus. Br J Dermatol 2005; 153: 558-564.
229. McKee PH, McClelland M, Sandford JC. Co-existence of pemphigus, anti-skeletal muscle antibody and a retroperitoneal paraganglioma. Br J Dermatol 1978; 99: 441-445.
230. Eccersley LRJ, Hoffbrand AV, Rustin MHA, McNamara CJ. Paraneoplastic pemphigus associated with systemic mastocytosis. Am J Hematol 2009; 84: 847-848.
231. Trüeb RM, Didierjean L, Fellas A, Elias A, Borradori L. Childhood bullous pemphigoid: report of a case with characterization of the targeted antigens. J Am Acad Dermatol 1999; 40: 338-344.
232. Chimanovitch I, Hamm H, Georgi M, et al. Bullous pemphigoid of childhood: autoantibodies target the same epitopes within the NC16A domain of BP180 as autoantibodies in bullous pemphigoid of adulthood. Arch Dermatol 2000; 136: 527-532.
233. Cliff S, Holden CA. Pemphigoid nodularis: a report of three cases and review of the literature. Br J Dermatol 1997; 136: 398-401.
234. Powell AM, Albert S, Gratian MJ, Bittencourt R, Bhogal BS, Black MM. Pemphigoid nodularis (non-bullous): a clinicopathological study of five cases. Br J Dermatol 2002; 147: 343-349.
235. Schmidt E, Sitaru C, Schubert B, et al. Subacute prurigo variant of bullous pemphigoid: autoantibodies show the same specificity compared with classic bullous pemphigoid. J Am Acad Dermatol 2002; 47: 133-136.
236. Korman NJ, Woods SG. Erythrodermic bullous pemphigoid is a clinical variant of bullous pemphigoid. Br J Dermatol 1995; 133: 967-971.
237. Alonso-Llamazares J, Dietrich SM, Gibson LE. Bullous pemphigoid presenting as exfoliative erythroderma. J Am Acad Dermatol 1998; 39: 827-830.
238. Levine N, Freilich A, Barland P. Localized pemphigoid simulating dyshidrosiform dermatitis. Arch Dermatol 1979; 115: 320-321.
239. Caldarola G, Fania L, Cozzani E, Feliciani C, De Simone C. Dyshidrosiform pemphigoid: a well-defined clinical entity?. Eur J Dermatol 2011; 21: 112-113.
240. Chan LS, Dorman MA, Agha A, Suzuki T, Cooper KD, Hashimoto K. Pemphigoid vegetans represents a bullous pemphigoid variant. Patient's IgG autoantibodies identify the major bullous pemphigoid antigen. J Am Acad Dermatol 1993; 28: 331-335.
241. Mora RG, Nesbitt LTJ, Brantley JB. Lichen planus pemphigoides: clinical and immunofluorescent findings in four cases. J Am Acad Dermatol 1983; 8: 331-336.
242. Lang PGJ, Maize JC. Coexisting lichen planus and bullous pemphigoid or lichen planus pemphigoides? J Am Acad Dermatol 1983; 9: 133-140.
243. Maceyko RF, Camisa C, Bergfeld WF, Valenzuela R. Oral and cutaneous lichen planus pemphigoides. J Am Acad Dermatol 1992; 27: 889-892.
244. Cohen DM, Ben-Amitai D, Feinmesser M, Zvulunov A. Childhood lichen planus pemphigoides: a case report and review of the literature. Pediatr Dermatol 2009; 26: 569-574.